Canadian researchers work together to develop made-in-Canada COVID-19 testing capacity
The road towards Canadian testing capacity began in Montreal
Rifampin for Latent TB: Shorter and safer than the standard treatment, but also cheaper
A new study shows that rifampin regimen is cheaper than isoniazid for latent tuberculosis
COVID-19 pandemic: the need for privacy and digital contact tracing
RI-MUHC researcher Abhinav Sharma calls for an approach emphasizing voluntary consent
COVID-19 impact on cancer patients: MUHC researchers take part in a multinational study
Published in The Lancet, the study reveals cancer-specific factors associated with increased mortality
Why do some non-smokers get COPD while many heavy smokers don’t?
A new study highlights a strong risk factor for COPD related to lung development
Hydroxychloroquine not effective in preventing the development of COVID-19 when used as post-exposure prophylaxis
A new study suggests that hydroxychloroquine is not effective in preventing the development of COVID-19 in individuals exposed to SARS-CoV-2
Interim Leadership of the Research Institute of the MUHC
The Board of Directors of the RI-MUHC is pleased to announce the appointment of Dr. Miguel N. Burnier, Jr. to the position of Interim Executive Director and Chief Scientific Officer of the RI-MUHC
Made-in-Canada COVID-19 test developed at McGill receives government support
Government support for McGill and RI-MUHC team in COVID-19 testing
COVID-19 Q&A: Tina Montreuil on helping children cope with anxiety
“It is not only what you say that matters, but what you do”
The RI-MUHC receives and tests the first UV-Disinfection robot in Canada
Novel robotics technology could potentially reduce healthcare-associated infections